BRPI0714553B8 - derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso - Google Patents

derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso

Info

Publication number
BRPI0714553B8
BRPI0714553B8 BRPI0714553A BRPI0714553A BRPI0714553B8 BR PI0714553 B8 BRPI0714553 B8 BR PI0714553B8 BR PI0714553 A BRPI0714553 A BR PI0714553A BR PI0714553 A BRPI0714553 A BR PI0714553A BR PI0714553 B8 BRPI0714553 B8 BR PI0714553B8
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical composition
camptothecin derivatives
camptothecin
compounds
Prior art date
Application number
BRPI0714553A
Other languages
English (en)
Portuguese (pt)
Inventor
Battaglia Arturo
Manzotti Carla
Samori Cristian
Bombardelli Ezio
Fontana Gabriele
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Publication of BRPI0714553A2 publication Critical patent/BRPI0714553A2/pt
Publication of BRPI0714553B1 publication Critical patent/BRPI0714553B1/pt
Publication of BRPI0714553B8 publication Critical patent/BRPI0714553B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
BRPI0714553A 2006-07-26 2007-07-13 derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso BRPI0714553B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001473A ITMI20061473A1 (it) 2006-07-26 2006-07-26 Derivati della camptotecina ad attivita antitumorale
ITMI2006A001473 2006-07-26
PCT/EP2007/006243 WO2008011994A1 (en) 2006-07-26 2007-07-13 Camptothecin derivatives with antitumor activity

Publications (3)

Publication Number Publication Date
BRPI0714553A2 BRPI0714553A2 (pt) 2013-03-26
BRPI0714553B1 BRPI0714553B1 (pt) 2020-11-17
BRPI0714553B8 true BRPI0714553B8 (pt) 2021-05-25

Family

ID=38668829

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714553A BRPI0714553B8 (pt) 2006-07-26 2007-07-13 derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso

Country Status (20)

Country Link
US (1) US8217053B2 (enExample)
EP (1) EP2044079B1 (enExample)
JP (1) JP5313894B2 (enExample)
KR (1) KR101412157B1 (enExample)
CN (1) CN101495486B (enExample)
AU (1) AU2007278500B2 (enExample)
BR (1) BRPI0714553B8 (enExample)
CA (1) CA2658900C (enExample)
DK (1) DK2044079T3 (enExample)
ES (1) ES2561356T3 (enExample)
HU (1) HUE027890T2 (enExample)
IL (1) IL196653A (enExample)
IT (1) ITMI20061473A1 (enExample)
MX (1) MX2009000827A (enExample)
NO (1) NO341812B1 (enExample)
PL (1) PL2044079T3 (enExample)
PT (1) PT2044079E (enExample)
RU (1) RU2450008C2 (enExample)
SI (1) SI2044079T1 (enExample)
WO (1) WO2008011994A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
KR101586030B1 (ko) * 2014-01-22 2016-01-15 주식회사 엘지생활건강 캄프토테신을 유효성분으로 포함하는 체모 성장 억제용 조성물
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
IL324591A (en) 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
CA3108044A1 (en) 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
US10568873B1 (en) * 2019-02-14 2020-02-25 United Arab Emirates University Safranal-sorafenib combination therapy for liver cancer
CN112225745B (zh) * 2020-11-16 2021-10-12 烟台大学 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
IL309457A (en) * 2021-06-17 2024-02-01 Minghui Pharmaceutical Hangzhou Ltd Compound against tumors and its use
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
CN121194979A (zh) * 2023-05-08 2025-12-23 甘李药业股份有限公司 喜树碱衍生物、接头、配体-药物偶联物及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
FR2757515B1 (fr) * 1996-12-20 2000-05-05 Sod Conseils Rech Applic Formes prodrogues et nouveaux analogues de la camptothecine, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6881555B2 (en) * 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
EP1430059B1 (en) * 2001-09-25 2006-03-01 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of 20(s)-camptothecins
US20060084167A1 (en) * 2004-10-16 2006-04-20 Cohenford Menashi A Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells

Also Published As

Publication number Publication date
MX2009000827A (es) 2009-02-03
KR101412157B1 (ko) 2014-06-25
PL2044079T3 (pl) 2016-06-30
AU2007278500B2 (en) 2012-06-07
NO341812B1 (no) 2018-01-29
PT2044079E (pt) 2016-03-09
JP5313894B2 (ja) 2013-10-09
US8217053B2 (en) 2012-07-10
IL196653A (en) 2015-04-30
IL196653A0 (en) 2009-11-18
ITMI20061473A1 (it) 2008-01-27
WO2008011994A1 (en) 2008-01-31
CN101495486A (zh) 2009-07-29
CA2658900C (en) 2015-09-15
SI2044079T1 (sl) 2016-02-29
RU2009102243A (ru) 2010-07-27
ES2561356T3 (es) 2016-02-25
KR20090033456A (ko) 2009-04-03
HK1135691A1 (en) 2010-06-11
BRPI0714553A2 (pt) 2013-03-26
NO20090251L (no) 2009-01-16
US20100120816A1 (en) 2010-05-13
JP2009544634A (ja) 2009-12-17
AU2007278500A2 (en) 2010-09-09
DK2044079T3 (en) 2016-02-29
EP2044079B1 (en) 2015-12-09
CA2658900A1 (en) 2008-01-31
HUE027890T2 (en) 2016-11-28
BRPI0714553B1 (pt) 2020-11-17
EP2044079A1 (en) 2009-04-08
RU2450008C2 (ru) 2012-05-10
AU2007278500A1 (en) 2008-01-31
CN101495486B (zh) 2013-05-15

Similar Documents

Publication Publication Date Title
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
BRPI0507198A (pt) derivados de bisariluréia
BRPI0513901A (pt) derivados de uréia cìclicos substituìdos, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase
BRPI1008473A2 (pt) compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0910388A2 (pt) agentes terapêutico antivirais.
BRPI0707302B8 (pt) compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BR112012011793A2 (pt) "acrilamidas heterocíclicas e seu uso como farmacêuticos"
MX384206B (es) Formulaciones de inhibidores de dpp iv
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
BR0315580A (pt) Derivados de metileno uréia
BRPI0815547B8 (pt) composição farmacêutica compreendendo depsipeptídeos cíclicos, e seus usos
BRPI0707704A8 (pt) derivados de antranilamida / 2-amino-heteroareno carboxamida
BRPI0514731A (pt) derivados de pirimidina
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
BR112012009310B8 (pt) composto derivados de 2-oxo-1-pirrolidinil imidazotiadiazol, uso dos mesmos e composição farmacêutica compreendendo os mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2679 DE 10-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.